Senate maintains HIV funding
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute U.S. House votes to cut spending for HIV/AIDS and hepatitis DAVID TAFFET | Senior Staff Writer Taffet@DallasVoice.com The U.S.
Senate Appropriations Committee took a bipartisan vote to maintain HIV and hepatitis prevention and treatment spending for 2025.
That contrasts with what House Republicans passed — a $700 million spending cut. That funding includes the Ending the HIV Epidemic or EHE in the U.S.
Initiative. “While disappointed that Congress will not be providing the necessary funding to really end HIV or hepatitis in the United States, given the severe budget constraints, what the Senate has proposed will allow existing programs to at least continue,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, in a statement. “Now, for the benefit of the country, it is up to the House to act in a responsible manner and fund the federal government at the necessary levels in a timely fashion.” Ending the HIV Epidemic in the U.S. (EHE) is a plan announced in 2019 during the Trump administration to end the HIV epidemic in the United States by 2030, according to the U.S.
